A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
Latest Information Update: 08 Nov 2023
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Bendamustine; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Filgrastim; Fludarabine; Fotemustine; Ifosfamide; Lenograstim; Melphalan; Mitoxantrone; Prednisone; Rituximab; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FIL-FLAZ-12
- 01 Nov 2023 Primary endpoint has not been met. (Progression Free Survival from randomization (rPFS), as per Results published in the Annals of Oncology
- 01 Nov 2023 Status changed from active, no longer recruiting to discontinued, as per Results published in the Annals of Oncology
- 01 Nov 2023 Results published in the Annals of Oncology